Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus Rhythm

NCT ID: NCT01266681

Last Updated: 2010-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Persistent Atrial Fibrillation (AF) is a common and distressing cardiac arrhythmia and accounts for 1% of the healthcare budget in the UK and it's prevalence is rising. Symptoms of atrial fibrillation include palpitations, chest pain , shortness of breath and fatigue, with quality of life measures reduced for patients with persistent AF, increased stroke risk and increased all cause mortality rates. DC Cardioversion is used to restore normal sinus rhythm in patients with persistent AF. It has a high success rate but reoccurence of AF is common. The use of anti arrhythmic drugs (AADs) can augment the number of patients remaining in sinus rhythm at one year, with amiodarone currently the most superior. Unfortunately it can have serious side affects. Dronedarone is a related drug designed specifically to minimise the most serious side affects and is no approved and used prominently in the management of non permanent AF. However it has not yet been studied in a post DC Cardioversion population.

Patients in persistent AF who are referred for elective DC Cardioversionwill be randomised to receive either Amiodarone or Dronedarone to compare the ability to help maintain sinu rhythm post cardioverion in one NHS hospital. Patients will be followed up for a year post cardioversion to see if they stay in sinus rhythm.

Ho: there will be no difference in maintenance of sinus rhythm with the use of amiodarone or dronedarone

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amiodarone

this group will be given Amiodarone to maintain sinus rhythm powst cardioversion.

Group Type ACTIVE_COMPARATOR

amiodarone

Intervention Type DRUG

Visit One:. Once consent is given patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.

Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.

Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires

Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires

Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires

Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires

Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.

Dronedarone

this group will be given dronedarone to maintain sinus rhythm post DC cardioversion

Group Type ACTIVE_COMPARATOR

Dronedarone

Intervention Type DRUG

Visit One: patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.

Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.

Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires

Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires

Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires

Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires

Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

amiodarone

Visit One:. Once consent is given patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.

Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.

Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires

Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires

Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires

Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires

Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.

Intervention Type DRUG

Dronedarone

Visit One: patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.

Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.

Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires

Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires

Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires

Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires

Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Patients with persAF requiring dc cardioversion.

* Patients must be over 18 years old.
* Patients give informed consent form prior to participating in this study.
* Patients must be on warfarin for at least 4 weeks or a transoesphageal ECHO must be performed at the time of dc cardioversion.

Exclusion Criteria

* • Patient is suffering with unstable angina in last 1 week.

* Patient has had a myocardial infarction within last 2 months.
* Patient is expecting or has had major cardiac surgery within last 2 months.
* Patient is participating in a conflicting study.
* Patient is mentally incapacitated and cannot consent or comply with follow-up.
* Patient has NYHA class III/ IV heart failure.
* Pregnancy.
* Patient suffers with other cardiac rhythm disorders.
* Recent coronary artery intervention or other factors suggesting clinical instability (ECG, clinical or laboratory findings).
* GFR\<30mls/min.
* Patients has a contraindication to amiodarone or dronedarone
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eastbourne General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

East Sussex Hospitals NHS Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eastbourne General Hospital

Eastbourne, East Sussex, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Steve Podd, MA, MRCP

Role: CONTACT

Phone: 01323 417400

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ACDC MainS

Identifier Type: -

Identifier Source: org_study_id